Supports exploratory, mechanistic, and epidemiologic studies on how co-infections (pathogenic and/or non-pathogenic, excluding HIV-only focus) influence carcinogenesis, risk, progression, survival, and disparities—aiming to reveal novel pathways and targets that can inform prevention and treatment of infection-related cancers. Clinical trials are not allowed.
Eligibility criteria:
-
Eligible applicant types include U.S. and foreign organizations; foreign components are allowed.
-
PD/PI must have an eRA Commons ID; Multiple PD/PI permitted.
-
Projects must be exploratory/novel and address co-infection (≥2 agents); single-pathogen or HIV-only studies are non-responsive.
-
Human subjects research allowed; no clinical trials (R21 mechanism).
-
Letters of support recommended for U.S./foreign partners; describe complementary expertise if multi-site.
Funding details:
-
Project period: up to 2 years.
-
Budget: up to USD 275,000 total direct costs over 2 years; no more than USD 200,000 in any single year.
Deadlines:
-
Oct 16, 2025.
Where to go for further information: